PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(02): 146-150
DOI: 10.4103/sajc.sajc_123_18
Original Article

Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer

M. Basade
Department of Medical Oncology, Saifee Hospital, Mumbai, Maharashtra
,
M. Singhal
Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi
,
A. K. Rathi
Department of Radiation Oncology, MAMC, New Delhi
,
M. Nandi
Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh
,
S. Minhas
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
,
S. Goswami
Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh
,
S. Shinde
Department of Radiation Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal
,
P. M. Parikh
Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra
,
S. Aggarwal
Department of Radiation Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal
› Institutsangaben Financial support and sponsorship: Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

Metastatic breast cancer (MBC) is cancer that has spread from the breast to another part of the body or has come back in another distant location. Treatment options for MBC depend on several factors, including where the cancer has spread, the patient's overall health, and the levels of hormone receptors and HER2 in the tumour. Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours.[7],[8],[9],[10] This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations in regards with the use of these agents and the management of HER2 positive MBC for the benefit of community oncologists.

Key words

Capecitabine - combination systemic therapy - docetaxel - lapatinib - personalized modification - pertuzumab - TDM1 - trastuzumab


Publikationsverlauf

Artikel online veröffentlicht:
22. Dezember 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-10.
  • 2 Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto breast cancer study group. J Clin Oncol 1998;16:1340-9.
  • 3 Hartmann LC, Ingle JN, Wold LE, Farr GH Jr., Grill JP, Su JQ, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
  • 4 Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
  • 5 Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
  • 6 Têtu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
  • 7 Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  • 8 Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
  • 9 Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94 Suppl 1:S5a.
  • 10 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
  • 11 Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G, et al. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer 2010;47:8-15.
  • 12 Nikhra P, Patel S, Taviad D, Chaudhary S. Study of ER (Estrogen Receptor), PR (Progesterone Receptor) and HER-2/NEU (Human Epidermal Growth Factor Receptor) expression by immunohistochemistry in breast carcinoma. Int J Biomed Adv Res 2014;5:275-8.
  • 13 Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, et al. Her-2/neu status: A neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev 2013;14:2231-5.
  • 14 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
  • 15 Falkson G, Gelman RS, Leone L, Falkson CI. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 1990;66:1621-9.
  • 16 Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
  • 17 Leach B. T-DM1 Approved for HER2-Positive Metastatic Breast Cancer. Available from: http://www.onclive.com/web-exclusives/t-dm1-approved-for-her2-positive-metastatic-breast-cancer.
  • 18 T-DM1 (Kadcyla) Wins FDA Approval. Available from: http://www.breastcancer.org/research-news/20130222-5.
  • 19 Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 2014;20:4436-41.
  • 20 Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
  • 21 Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013;31:1157-63.
  • 22 Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer previously treated with chemotherapy and 2 or more HER2-targeted agents: Results from the T-PAS expanded access study. Cancer J 2015;21:357-64.
  • 23 Jacot W, Jean-Sébastien Frenel EP, Guiu S, Levy C. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Research and Treatment 2016;157:307-18.
  • 24 Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
  • 25 Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-6.
  • 26 Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71.
  • 27 Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34.
  • 28 Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, et al. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 2014;120:1932-8.
  • 29 Yip CH, Taib NA, Mohamed I. Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev 2006;7:369-74.
  • 30 Tan EY, Wong HB, Ang BK, Chan MY. Locally advanced and metastatic breast cancer in a tertiary hospital. Ann Acad Med Singapore 2005;34:595-601.
  • 31 Lim SE, Back M, Quek E, Iau P, Putti T, Wong JE, et al. Clinical observations from a breast cancer registry in Asian women. World J Surg 2007;31:1387-92.
  • 32 Chopra R. The Indian scene. J Clin Oncol 2001;19:106S-111S.
  • 33 Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2014;145:725-34.
  • 34 Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: Are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer 2015;112:1445-51.
  • 35 Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study. Oncotarget 2017;8:27990-6.
  • 36 Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99.
  • 37 Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-63.
  • 38 Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704.
  • 39 Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-44.
  • 40 Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
  • 41 Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
  • 42 Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9.
  • 43 Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9.
  • 44 Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. Br J Cancer 2010;102:995-1002.
  • 45 Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22:625-30.
  • 46 Iwata H, Narabayashi M, Ito Y, Saji S, Fujiwara Y, Usami S, et al. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: Subset analysis of Japanese patients. Int J Clin Oncol 2013;18:621-8.
  • 47 Ro J, Park S, Kim S, Kim TY, Im YH, Rha SY, et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: An open-label expanded access study in Korea. BMC Cancer 2012;12:322.
  • 48 Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 2013;14:64-71.
  • 49 Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-82.
  • 50 Herceptin (Trastuzumab) Package Insert. South San Francisco, CA: Genentech, Incorporated; 2009.
  • 51 Yu AF, Yadav NU, Eaton AA, Lung BY, Thaler HT, Liu JE, et al. Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist 2015;20:1105-10.
  • 52 Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist 2017;22:642-7.
  • 53 Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, et al. Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer. Oncologist 2016;21:418-24.